Abstract | PURPOSE OF REVIEW: The recent advances in the use of targeted therapy in pancreatic cancer are based on the knowledge of genetic alterations that occur during pancreatic carcinogenesis. We describe the repository of frequent alterations targeting tumour suppressor genes and oncogenes. We focus our attention on the epidermal growth factor receptor signalling pathway, which can be activated through different alterations and seems to play a central role in the cell transformation. Multiple targeted drugs have been developed against different partners of this network trying to improve the treatment of pancreatic cancer patients. RECENT FINDINGS: SUMMARY:
|
Authors | Pierre Laurent-Puig, Julien Taieb |
Journal | Current opinion in oncology
(Curr Opin Oncol)
Vol. 20
Issue 4
Pg. 454-8
(Jul 2008)
ISSN: 1531-703X [Electronic] United States |
PMID | 18525343
(Publication Type: Journal Article, Review)
|
Chemical References |
- Protein Kinase Inhibitors
- Quinazolines
- Erlotinib Hydrochloride
- ErbB Receptors
|
Topics |
- Clinical Trials as Topic
- ErbB Receptors
(antagonists & inhibitors)
- Erlotinib Hydrochloride
- Humans
- Pancreatic Neoplasms
(drug therapy)
- Protein Kinase Inhibitors
(therapeutic use)
- Quinazolines
(therapeutic use)
- Research Design
(trends)
|